产品中心Cell Resources
联系我们CONTACT US
400-999-210024小时服务热线
产品概述
名称 | JIMT-1 (人乳腺癌细胞) (STR鉴定正确) |
别称 | JIMT1; JIMT |
种属 | 人 |
生长特性 | 贴壁细胞 |
细胞形态 | 上皮细胞样,单层生长 |
冻存条件 | 冻存液:55% 基础培养基+40%FBS+5%DMSO 温度:液氮 |
培养方案A(默认) |
培养条件:
气相:空气,95%;CO2,5%, 温度:37℃
|
推荐传代比例 | 1:2-1:8 |
推荐换液频率 | 2-3次/周 |
背景描述 | established from the pleural effusion of a 62-year-old woman with ductal breast cancer (grade 3 invasive, T2N1M0) after postoperative radiation in 2003; cell line was described in the literature to carry an amplified HER-2 oncogene and to be insensitive to HER-2-inhibiting drugs, e.g. trastuzumab (Herceptin); listed in the CCLE (ref 18232) |
年龄(性别) | 女性;62岁 |
细胞类型 | 肿瘤细胞 |
肿瘤类型 | 乳腺导管癌 |
生物安全等级 | BSL-1 |
倍增时间 | ~30-40 hours (DSMZ=ACC-589); 35.39 hours (GrayJW panel) |
保藏机构 | AddexBio; C0006005/50 DSMZ; ACC-589 |
STR鉴定
-
STR位点信息
Amelogenin X CSF1PO 12,13 D2S1338 24 D3S1358 18 D5S818 12,13,14 D7S820 12 D8S1179 10,13 D13S317 8,13 D16S539 11 D18S51 10 D19S433 12,13 D21S11 27,31.2 FGA 21,23 PentaD 9,12 PentaE 7,19 TH01 7 TPOX 8 vWA 18 D6S1043 11 D12S391 17 D2S441 11.3,14 -
STR鉴定图
-
参考文献
-
Characterization of a novel T cell-engaging bispecific antibody for elimination of L1CAM-positive tumors (2024-04-11)
期刊:BIOMEDICINE & PHARMACOTHERAPY
DOI:10.1016/j.biopha.2024.116565
影响因子 :7.5
引用产品: JIMT-1 细胞
-
Prognostic and immune correlation of IDO1 promoter methylation in breast cancer (2024-11-13)
期刊:Scientific Reports
DOI:10.1038/s41598-024-79149-w
影响因子 :3.8
引用产品: DMEM高糖 培养基 , T-47D 细胞 , JIMT-1 细胞 , MDA-MB-231 细胞 , SUM159PT 细胞 , MEM完全培养基(含10% FBS) , 特级胎牛血清 , A549 [A-549] 细胞 , MCF7 [MCF-7] 细胞 , ZR-75-1 细胞 , 青霉素-链霉素溶液(双抗),100× , RPMI-1640 培养基 , HCC1806 细胞
-
CD24 May Serve as an Immunotherapy Target in Triple-Negative Breast Cancer by Regulating the Expression of PD-L1 (2023-12-31)
期刊:Breast Cancer-Targets and Therapy
影响因子 :2.6
引用产品: ZR-75-1 细胞 , MCF7 [MCF-7] 细胞 , JIMT-1 细胞 , MDA-MB-468-06 细胞 , MDA-MB-231 细胞 , SK-BR-3 [SKBR3] 细胞
FAQs
Q:{{item.question}}
A:
产品资料


识别码示意图